Valuation: Genovis AB

Market Cap 1.34B 141M 122M 114M 104M 196M 13.41B 199M 524M 6.71B 528M 516M 22.39B P/E 2026 *
62.9x
P/E 2027 * 39.6x
Enterprise Value 1.23B 129M 112M 105M 95.4M 180M 12.29B 183M 480M 6.15B 484M 473M 20.53B EV / Sales 2026 *
8.33x
EV / Sales 2027 * 6.43x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 05/05/2015
Director of Finance/CFO 55 01/01/2022
Chief Tech/Sci/R&D Officer 42 01/01/2017
Director TitleAgeSince
Director/Board Member 77 01/01/2014
Director/Board Member 65 01/01/2019
Chairman 74 05/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.27%+3.32%+201.26%+363.87% 22.44B
+0.68%+1.65%-40.77%-21.44% 9.97B
-0.15%+22.19%+375.06%+15.62% 7.63B
-1.11%+43.73%-23.40% - 6.61B
-0.30%-0.43%+79.56%+45.91% 6.59B
-1.45%+0.75%-12.28%-13.75% 5.71B
-2.05%+9.51%+78.56%+100.57% 4.49B
+0.39%+2.79%-7.15%-16.31% 4.36B
-0.70%-4.54%-20.34%-35.79% 2.78B
Average -0.66%+54.16%+70.06%+54.84% 7.84B
Weighted average by Cap. -0.71%+83.92%+106.78%+134.05%

Financials

2026 *2027 *
Net sales 147M 15.48M 13.41M 12.56M 11.46M 21.56M 1.48B 21.92M 57.69M 739M 58.12M 56.85M 2.47B 185M 19.5M 16.89M 15.82M 14.43M 27.16M 1.86B 27.61M 72.66M 931M 73.2M 71.6M 3.1B
Net income 15.7M 1.65M 1.43M 1.34M 1.22M 2.3M 157M 2.34M 6.15M 78.79M 6.2M 6.06M 263M 33.6M 3.53M 3.06M 2.87M 2.61M 4.92M 337M 5M 13.16M 169M 13.26M 12.97M 563M
Net Debt -111M -11.67M -10.11M -9.47M -8.64M -16.25M -1.11B -16.53M -43.49M -557M -43.81M -42.86M -1.86B -145M -15.24M -13.21M -12.37M -11.28M -21.23M -1.45B -21.59M -56.81M -728M -57.23M -55.99M -2.43B
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-